COGT - NASDAQ
Cogent Biosciences, Inc.
$32.26
+0.19%Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live Snapshotcogt
Additional Paid-In Capital
Last Annual Value
1.73B
3-Year CAGR
42%
5-Year CAGR
40%
10-Year CAGR
%
Cogent Biosciences, Inc. Competitors Analysis of Additional Paid-In Capital
| Company | Additional Paid-In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Cogent Biosciences, Inc. NASDAQ:COGT | 1.73B | 29.4% | 34.1% | 107.7% | |
 Liquidia Corporation NASDAQ:LQDA | 670.97M | 12.1% | 12.4% | 26.1% | |
 89bio, Inc. NASDAQ:ETNB | 1.22B | 7.2% | 29.3% | N/A | |
 Denali Therapeutics Inc. NASDAQ:DNLI | 3.06B | 12.6% | 13.7% | 78.4% | |
 Recursion Pharmaceuticals, Inc. NASDAQ:RXRX | 0.00 | N/A | N/A | N/A | |
 ImmunityBio, Inc. NASDAQ:IBRX | 3.20B | 10.4% | 13.2% | N/A | |
 Viridian Therapeutics, Inc. NASDAQ:VRDN | 1.93B | 26.1% | 36.1% | 80.9% | |
 Ocular Therapeutix, Inc. NASDAQ:OCUL | 1.81B | 31.9% | 23.4% | 23.1% | |
 Arcus Biosciences, Inc. NYSE:RCUS | 0.00 | N/A | N/A | N/A | |
 Agios Pharmaceuticals, Inc. NASDAQ:AGIO | 2.56B | 1.6% | 1.8% | 11.7% |
Cogent Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your COGT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.